You’ve heard this one before. The reason American seniors and patients are charged by far the highest prescription drug prices in the world is because the pharmaceutical industry needs to make up for their massive investment in research and development (R&D).

The way pharma industry CEOs and lobbyists talk about it, it’s as if every dollar in profit they make goes right back into finding the next penicillin. They say it’s unfortunate one-in-four American patients are unable to afford their prescribed medicines, but it’s for the greater good.

Trying to undo Medicare’s deal

This is one of the arguments at the center of a myriad of lawsuits the drug makers have leveled against the Biden administration — desperately trying to undo Medicare’s historic new authority under the Inflation Reduction Act to negotiate lower drug prices.

The administration quickly exercised this power on behalf of millions of struggling patients, choosing 10 extremely expensive, life-saving drugs for the first round of negotiation, including cancer and diabetes treatments.

Advertise with us

While new polling shows most Americans are behind the President’s drug pricing action, most of the eight companies that make these medicines have opted to sue instead of coming to the table with reasonable prices.

Big Pharma insists they won’t be forced to cut into their investment in R&D. But here’s the thing: they don’t have to. It’s a simple matter of priorities, and they have prioritized profits over patients.

At Accountable.US, we examined the public filings and earnings reports of these eight companies including Johnson & Johnson, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck, Novartis and Novo Nordisk.

Spending choices

Our report found they collectively spent far less on R&D compared to the vast sums they threw at non-essential things like political activity, lobbying, executive bonuses, and handouts to wealthy investors.

While these companies spent a total of $95.9 billion on R&D expenses in 2023, they spent 70% more, $162 billion, on stock buybacks, dividends, and marketing and administrative costs. They spent nearly $500 million on compensation for their boards and executives, as well as at least $83.2 million on trade association dues, $10.6 million on political contributions and $57.8 million on lobbying.

Advertise with us

Meanwhile, these corporations boasted of a staggering $367 billion in sales. A 2020 study found the pharmaceutical industry was more profitable than other large public companies. Tell me again how the sky is falling?

Conveniently, the big drug companies never put their R&D spending in proper perspective. Four of the companies spent more on combined payments to shareholders in the form of stock buybacks and dividends than they did on research and development in 2023.

Five of the eight companies spent more on administrative and marketing expenses than R&D in 2023. In all, the eight companies paid their chief executive officers an average of about $20.7 million in total compensation in 2023.

The price to seniors

Despite what Big Pharma’s lawyers and lobbyists claim, executives could have passed record profits onto patients with more reasonable prices. They chose not to.

They could have spent less on lobbying and enriching executives than charging thousands more for a single cancer or diabetes treatment pill. But time and again, the industry chose greed to benefit the wealthy few at the expense of millions of seniors and sick patients.

Advertise with us

Of course, R&D is a worthy and necessary investment. But that’s not what this is really about. This is about protecting profits, whatever the cost. Our seniors should not have to pay that price.

Tony Carrk is the executive director of Accountable.US.